For the quarter ending 2026-03-31, CLDX made $15K in revenue. -$79,789K in net income. Net profit margin of -531926.67%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues | 15 | 120 | - | 730 |
| Research and development | 73,001 | 75,333 | 62,931 | 54,196 |
| General and administrative | 11,449 | 11,941 | 10,686 | 10,391 |
| Total operating expenses | 84,450 | 87,274 | 73,617 | 64,587 |
| Operating loss | -84,435 | -87,154 | -73,617 | -63,857 |
| Investment and other income, net | 5,750 | 5,837 | 6,573 | 7,257 |
| Net loss | -78,685 | -81,317 | -67,044 | -56,600 |
| Unrealized (gain) loss on marketable securities | -1,104 | -139 | 426 | -229 |
| Comprehensive loss | -79,789 | -81,456 | -66,618 | -56,829 |
| Basic EPS | -1.18 | -0.307 | -1.01 | -0.85 |
| Diluted EPS | -1.18 | -0.307 | -1.01 | -0.85 |
| Basic Average Shares | 66,566,000 | 265,488,805 | 66,420 | 66,392 |
| Diluted Average Shares | 66,566,000 | 265,488,805 | 66,420 | 66,392 |
Celldex Therapeutics, Inc. (CLDX)
Celldex Therapeutics, Inc. (CLDX)